Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Minodronic acid

Base Information Edit
  • Chemical Name:Minodronic acid
  • CAS No.:155648-60-5
  • Molecular Formula:C9H14N2O8P2
  • Molecular Weight:340.16400
  • Hs Code.:
  • Mol file:155648-60-5.mol
Minodronic acid

Synonyms:Minodronic Acid Hydrate;

Suppliers and Price of Minodronic acid
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • TCI Chemical
  • Minodronate Monohydrate >98.0%(HPLC)
  • 25mg
  • $ 239.00
  • DC Chemicals
  • Minodronicacidmonohydrate >98%
  • 1 g
  • $ 800.00
  • DC Chemicals
  • Minodronicacidmonohydrate >98%
  • 250 mg
  • $ 400.00
  • DC Chemicals
  • Minodronicacidmonohydrate >98%
  • 100 mg
  • $ 200.00
  • Crysdot
  • (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonicacidhydrate 97%
  • 1g
  • $ 160.00
  • Crysdot
  • (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonicacidhydrate 97%
  • 10g
  • $ 820.00
  • Crysdot
  • (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonicacidhydrate 97%
  • 5g
  • $ 480.00
  • Chem-Impex
  • Minodronatemonohydrate,98%(HPLC) 98%(HPLC)
  • 25MG
  • $ 275.52
  • Chemenu
  • (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonicacidhydrate 97%
  • 5g
  • $ 449.00
  • Chemenu
  • (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonicacidhydrate 97%
  • 10g
  • $ 767.00
Total 103 raw suppliers
Chemical Property of Minodronic acid Edit
Chemical Property:
  • Refractive Index:1.744 
  • PSA:181.44000 
  • Density:1.97g/cm3 
  • LogP:-0.18600 
  • Storage Temp.:2-8°C 
  • Water Solubility.:Insoluble in water 
Purity/Quality:

99%, *data from raw suppliers

Minodronate Monohydrate >98.0%(HPLC) *data from reagent suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:

SDS file from LookChem

Useful:
  • Clinical Use The bone resorption inhibitor minodronic acid hydrate was approved and introduced last year in Japan, bringing the total number of bis-phosphonates marketed for this indication to seven. There are an estimated 10 million current and potential osteoporosis sufferers in Japan, a number that is expected to continue growing due to the country’s aging population. Minodronic acid is the first drug to show a significant effect in preventing bone fractures as compared to placebo in a Japanese patient population. Minodronic acid was co-developed by Astellas and Ono, who are marketing the drug as Bonoteo and Recalbon, respectively.
Post RFQ for Price